Talimogene laherparepvec (T-VEC), a herpes simplex virus type 1–derived oncolytic immunotherapy, improved durable response rate (DRR) and overall survival (OS) in patients with advanced melanoma in a randomized, prospective phase 3 trial.1
MRV Research
Atezolizumab/Vemurafenib Combo Shows Clinical Activity in BRAF+ Melanoma
The combination of atezolizumab (MPDL3280A) and vemurafenib (Zelboraf) yielded durable responses in patients with previously untreated BRAF V600–mutated metastatic melanoma in an ongoing phase Ib study.1
Blood Test that Monitors Dead Cancer Cell DNA Better at Tracking Spread of Melanoma
Physicians treating patients with metastatic melanoma — one of the most aggressive forms of skin cancer — may soon have a superior tool in their efforts to closely track the disease.
Risk Factors for Melanoma and Genetic Testing
Although cutaneous melanoma results in more years of life lost than any adult cancer except breast cancer, 98% of local cases are cured. In fact, a 10-year study conducted in Schleswig-Holstein, an area of Germany, found that a screening program reduced mortality from 1.9 per 100,000 people to one death per 100,000.